Placebo News and Research

RSS

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

Estrogen replacement therapy is associated with a significant decrease in anxiety symptoms among girls with anorexia nervosa, a new clinical trial finds. The results will be presented today at The Endocrine Society's Annual Meeting in San Francisco.

18 Jun 2013

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

TWi Biotechnology, Inc. announced that it has completed the patient enrollment in a phase II trial of AC-201 for Gout Flare Prophylaxis during urate-lowering therapy. This randomized, double-blind, placebo-controlled Phase II study is conducted in 8 major medical centers in Taiwan.

18 Jun 2013

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Vanda Pharmaceuticals Inc. presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms.

18 Jun 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Santarus, Inc. and Pharming Group NV today announced that the U.S. Food and Drug Administration has accepted for filing the Biologics License Application for the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 IU/kg.

18 Jun 2013

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàrl was today notified that the European Commission has amended the marketing authorisation for REVLIMID. This decision means that REVLIMID is now approved to treat patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

17 Jun 2013

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.

15 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

13 Jun 2013

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

New PSUMMIT 2 data first presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, further demonstrate the efficacy of ustekinumab in Psoriatic Arthritis (PsA).

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Research: Sleep mechanism enables brain to consolidate emotional memory

Sleep researchers from University of California campuses in Riverside and San Diego have identified the sleep mechanism that enables the brain to consolidate emotional memory and found that a popular prescription sleep aid heightens the recollection of and response to negative memories.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that treatment with brodalumab demonstrates significant clinical response and an acceptable safety profile in subjects with psoriatic arthritis.

13 Jun 2013

Study: Vitamin C may reduce bronchoconstriction caused by exercise

Vitamin C may substantially reduce bronchoconstriction caused by exercise, says Dr. Harri Hemila from the University of Helsinki, Finland. Hemila's meta-analysis "Vitamin C may alleviate exercise-induced bronchoconstriction" was published in BMJ Open (7 June, 2013)

12 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms.

12 Jun 2013

Placebo News and Research

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Estrogen replacement therapy reduces anxiety symptoms in girls with anorexia nervosa

TWi Biotechnology completes patient enrollment in phase II trial of AC-201 for Gout Flare Prophylaxis

Vanda presents additional data from tasimelteon Phase III studies at ENDO 2013

Santarus, Pharming Group announce FDA acceptance of RUCONEST BLA

Vaccine given to newborns 60% effective against rotavirus in Ghana

European Commission amends marketing authorisation for Celgene's REVLIMID

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Teva to present abstracts on AZILECT at MDS meeting

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Study: Tocilizumab is effective in children with juvenile idiopathic arthritis

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Research: Sleep mechanism enables brain to consolidate emotional memory

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

Study: Vitamin C may reduce bronchoconstriction caused by exercise

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Researchers to launch Phase II clinical trial to investigate potential new therapy for sickle cell anemia

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News